Navigation Links
Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Date:12/3/2008

rmalities were observed during the study. The only side effect observed was mild loose stools (12% in treatment group vs. 3% in the placebo group). To date, no significant toxicities have been observed in any of the animal studies with doses ranging from 2000 mg/kg/day in dogs to 16,000 mg/kg/day in rodents.

"The positive results of Menerba to date are very encouraging. Our discussions with the FDA clinical staff, our Scientific Advisory Board, our clinical investigators, and our reception at the many scientific conferences at which we have presented -- all have served to strengthen our confidence that Bionovo's Menerba will be able to provide menopausal women with a safe and efficacious alternative to the existing drugs on the market. This is particularly important because all current drugs for hot flashes carry six black box warnings by the FDA for potentially serious adverse events. As a next step, we have plans to meet with the clinical review team at the FDA to reach an agreement on the clinical path forward," said Dr. Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

"Menerba provides a true paradigm shift in the treatment of menopausal hot flashes. The novel mechanism of action, the exciting preclinical and clinical safety, and the early efficacy are encouraging. I believe swift development is warranted so we can provide women with an alternative to hormone therapy," said Wulf Utian, M.D., Ph.D., D.Sc. Founder and President Emeritus of the

North American Menopause Society and Menerba's Principal Clinical Investigator.

The Company expects to initiate clinical trials by the second quarter of 2009 subject to FDA review.

About Menerba

Menerba is an estrogen receptor (ER) beta selective drug developed as an alternative to postmenopausal hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... , , PHOENIX, ... published two new publications on hormone therapies and their effects on ... , Cardiovascular disease caused by atherosclerosis, or the build-up ... of American women--40% of total deaths--and the rate of mortality is ...
... OMER and MIGDAL HA,EMEK, Israel, August 3 ,Medigus ... visualization,medical devices, and Tower Semiconductor, Ltd. (Nasdaq: ... today announced successful,sampling of a new CMOS imager that ... its new medical devices camera; the smallest of its,kind ...
Cached Medicine Technology:TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 2TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 2Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 3Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor 4
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... January 22, 2015 State Forestry Institute ... management system with support from GEOSYSTEMS, a dedicated Hexagon ... solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... as well as point clouds and documents. This effort ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... chain of coffee cafes, on opening its 300th outlet in Mumbai ... of 500 by the year 2007. // ,"It ... have played a large role in firmly establishing the coffee café ... Bean Coffee Trading Company Ltd., the parent company of the chain. ...
... survey that found that almost 80 percent of Shanghai women ... ,Yu Junde, coordinator of Survey and head official of Shanghai ... wearing of bras which could affect their health. ... 18 to 50, which revealed that many were wearing very ...
... been documented in Acute Coronary Syndrome patients, instituted aggressive ... Society for Cardiovascular Angiography and Interventions (SCAI) // 29th ... ,By combining data from nine randomized clinical trials and ... analysis was able to put a sharper focus on ...
... have now identified a signaling pathway in the brain, ... food intake. Furthermore, this pathway linked to the development ... weight loss methods in obese individuals. ,Scientists ... pathway mTOR--activated by nutrient and hormonal signals--plays a role ...
... to the belief that adolescent boys tend to take romance ... it comes to heart matters, they might not be so ... is seen outside, an adolescent boy fails to communicate his ... mind. ,Boys are more vulnerable and emotionally engaged ...
... at the Gladstone Institute of Neurological Disease have now ... protein, apolipoprotein E, is indeed produced by neurons.// The ... established a definitive association between the two. ... common forms, one of which, apoE4, is the major ...
Cached Medicine News:Health News:Shanghai Women Don their Bras Improperly 2Health News:Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival 2Health News:Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3Health News:Alzheimer's-linked apolipoprotein E produced by neurons, Gladstone study 2
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... are designed to provide distraction of ... disc removal, endplate preparation, and insertion ... of several Vertebral Spreaders, Intradiscal Wedges, ... Vertebral Body Positioner. Used in ALIF ...
... is a point-of-care system designed for the ... to as Platelet Rich Plasma - PRP) ... small sample of blood. The Symphony II ... which are found in the platelets. The ...
... gel has an extensive base of experience ... platelet gel. When concentrated autologous platelets are ... structural and functional changes involved in coagulation ... a number of factors including serotonin, fibronectin, ...
Medicine Products: